This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Today we'll take a ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jennifer E. Ho, MD ...

Of the estimated five million patients in the U.S. diagnosed with heart failure annually, nearly half will have heart failure with preserved ejection fraction (HFpEF). Also known as diastolic heart ...

Phenotyping in HFpEF aids in tailoring therapies, addressing comorbidities, and improving patient outcomes. Artificial intelligence models effectively diagnose HFpEF and predict mortality, enhancing ...

Patients with heart failure with preserved ejection fraction (HFpEF) may experience worsened exercise tolerance if they also have anemia. The exercise stress echocardiographic study included nearly ...

Please provide your email address to receive an email when new articles are posted on . Maladaptations at the microvascular level may be involved in the pathophysiology of HF with preserved ejection ...

On 29 March, Dr. Sarah Birkhoelzer, presented results from the open-label, Phase IIa trial of ninerafaxstat during a moderated poster contributions session at this year’s American College of ...

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below: Receive the the latest news, research, and presentations from major meetings ...

ENCINITAS, Calif. and WROCLAW, Poland, Oct. 13, 2025 /PRNewswire/ -- Vasa Therapeutics, ("Vasa"), a private, clinical stage biotechnology company developing novel therapies for cardiovascular and ...